C. Crljenica

Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS).

L. Räber, S. Cook, S. Windecker, 2019, Journal of the American College of Cardiology.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, The Lancet.

Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study

F. Mach, K. Koskinas, D. Nanchen, 2021, Advances in Therapy.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, Lancet.